Manufacturing

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Articles

Yimmugo, which was introduced in Europe at the end of 2022, could be on the market in the US within months.

FDA Approves Immunoglobulin Therapeutic to Treat Primary Immunodeficiencies

Videos

Sander Van Gessel, MEng, Business Unit Director, DFE Pharma, discusses the important components of nitrosamine impurities from a manufacturing point of view as a part of his session, "Reducing Nitrosamines Without the Use of Scavengers: The Critical Role of Excipients - An Excipient Manufacturer's View."

Crucial Points from a Manufacturing Perspective (PDA/FDA Joint Regulatory Conference 2023)

Sander Van Gessel, MEng, Business Unit Director, DFE Pharma, discusses the recent findings of nitrosamine impurities in human drugs as a part of his session, "Reducing Nitrosamines Without the Use of Scavengers: The Critical Role of Excipients - An Excipient Manufacturer's View."

The Recent Discoveries of Nitrosamine Impurities (PDA/FDA Joint Regulatory Conference 2023)

There are many promising trials in the pipeline that may bring big news for major therapeutic areas.

Clinical Trials and their Impact on the Pharma Industry

Twist Bioscience is a synthetic biology and genomics company that has developed a DNA synthesis platform to industrialize the engineering of biology, which is a new method of this process by “writing” DNA on a silicon chip.

Ono Pharmaceutical Enters Drug Discovery Collaboration Agreement with Twist Bioscience

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

The industry is taking steps to automate the final product inspection process for complex therapeutics.

Progressing Finished Product Inspection Through Automation

WuXi STA’s new high-potency injectable line has an annual capacity of 12 million units.

WuXi Sta Launches High Potency Manufacturing Line in Wuxi City Location

Detection of nitrosamines in several commercial drugs has resulted in manufacturing batch recalls followed by a review of the APIs’ synthesis processes by MAHs. 

Understanding Nitrosamine Impurities in the Pharmaceutical Industry

The new method was developed to isolate tissue-specific EVs from the blood in addition to using a workflow to analyze their diverse multi-omics content. 

Mursla Bio Discovers New Biomarker Approach in Precision Medicine

The first CleanCap analog was launched in 2017, and since then, the capping technology has been incorporated in one of the first commercially approved COVID-19 vaccines.

Manufacturing, Drug Products